Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

G1-S-specific cyclin-D1 inhibitor

DRUG CLASS:

G1-S-specific cyclin-D1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

omacetaxine mepesuccinate (4)

omacetaxine mepesuccinate (4)

›

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
IDH2 mutation	Glioma	IDH2 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D